EGFR and head and neck squamous cell carcinoma: One of the monoclonal antibody-based drugs targeting EGFR, cetuximab’s efficacy was evaluated in combination with RT for HNC patients, demonstrating enhanced RT effectiveness and its significant role as a ‘radiosensitizer’, leading to FDA approval of such therapy for locally advanced HNSCC [32,47,56].